- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.12. | CHIMERIC THERAPEUTICS LIMITED: CDH17 granted FDA Orphan Drug Designation for Gastric Cancer | - | ASX | ||
| 27.11. | CHIMERIC THERAPEUTICS LIMITED: Company update-board changes, shareholder feedback & support | - | ASX | ||
| 26.11. | CHIMERIC THERAPEUTICS LIMITED: Final Director's Interest Notice - PH | - | ASX | ||
| 25.11. | CHIMERIC THERAPEUTICS LIMITED: Results of Meeting | 1 | ASX | ||
| 24.11. | CHIMERIC THERAPEUTICS LIMITED: Presentation to AGM | - | ASX | ||
| 24.11. | CHIMERIC THERAPEUTICS LIMITED: CHIMERIC RECEIVES $4.5M R&D TAX INCENTIVE | - | ASX | ||
| 13.11. | CHIMERIC THERAPEUTICS LIMITED: 75% disease control observed in CHM CDH17 trial | 2 | ASX | ||
| 13.11. | CHIMERIC THERAPEUTICS LIMITED: CHM CORE NK Combination Phase 1b trial update | 1 | ASX | ||
| CHIMERIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.11. | CHIMERIC THERAPEUTICS LIMITED: Pause in Trading | 1 | ASX | ||
| 06.11. | CHIMERIC THERAPEUTICS LIMITED: Response to ASX Query Letter | - | ASX | ||
| 31.10. | CHIMERIC THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 26.10. | CHIMERIC THERAPEUTICS LIMITED: Notice of Annual General Meeting/Proxy Form | 2 | ASX | ||
| 10.10. | CHIMERIC THERAPEUTICS LIMITED: Becoming a substantial holder | - | ASX | ||
| 10.10. | CHIMERIC THERAPEUTICS LIMITED: Notification regarding unquoted securities - CHM | 1 | ASX | ||
| 10.10. | CHIMERIC THERAPEUTICS LIMITED: Application for quotation of securities - CHM | - | ASX | ||
| 08.10. | CHIMERIC THERAPEUTICS LIMITED: Presentation to investor webinar | 1 | ASX | ||
| 03.10. | CHIMERIC THERAPEUTICS LIMITED: Investor update webinar - 11am AEDT, Wednesday 8 Oct | 1 | ASX | ||
| 02.10. | CHIMERIC THERAPEUTICS LIMITED: Additional complete responses in CHM CORE-NK Phase 1b trial | - | ASX | ||
| 29.09. | Hot Stocks: Chimeric Therapeutics, Dreadnought Resources, Nyrada | 3 | Finance News Network | ||
| 29.09. | CHIMERIC THERAPEUTICS LIMITED: Disease control and tumour shrinkage observed in CHM CDH17 | - | ASX |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 4,775 | +13,69 % | Recursion jumps as J.P. Morgan upgrades on lead program | ||
| QIAGEN | 38,480 | +1,29 % | QIAGEN NV steht still - für mich ist das kein Stillstand! | ||
| IMMUNOME | 20,600 | -11,93 % | Immunome-Aktie fällt nach Ankündigung einer Kapitalerhöhung über 400 Mio. US-Dollar | ||
| AVIDITY BIOSCIENCES | 71,87 | -0,14 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| KYVERNA THERAPEUTICS | 7,170 | -30,05 % | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock | EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) ("Kyverna"), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients... ► Artikel lesen | |
| BIONTECH | 78,00 | -0,64 % | Erfreuliche Studiendaten verleihen der BioNTech-Aktie wieder Rückenwind, doch für einen Durchbruch reicht es noch nicht | Vor fünf Jahren dominierte die Aktie von BioNTech noch das Börsengeschehen, mittlerweile schafft das Papier es aber nur noch selten auf das Radar der Anleger. Das Geschäft mit Corona-Impfstoffen ist... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 61,31 | -0,60 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 267,12 | -2,79 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 32,720 | -4,47 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| KYMERA THERAPEUTICS | 81,33 | -3,32 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| VOR BIOPHARMA | 14,380 | -9,27 % | Vor Biopharma: TD Cowen startet mit Kaufempfehlung und verweist auf Telitacicept-Potenzial | ||
| MINERALYS THERAPEUTICS | 37,420 | +3,92 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| COGENT BIOSCIENCES | 40,000 | +0,10 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,250 | +0,12 % | Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development | ||
| IMMUNOVANT | 26,830 | +0,75 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails |
Das Unternehmen CHIMERIC THERAPEUTICS LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHIMERIC THERAPEUTICS LIMITED finden Sie auf Wallstreet Online.